Verve Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Verve Therapeutics generated cash of -$149,549,000, which is less than the previous year. Cash used in financing activities reached the amount of $212,577,000 last year. Net change in cash is therefore $90,718,000.
Cash Flow
| 2019 | -7.44M | -12.75M | 17.95M |
|---|---|---|---|
| 2020 | -35.26M | -51.12M | 92.62M |
| 2021 | -77.88M | -239.09M | 377.08M |
| 2022 | -122.33M | -155.95M | 328.95M |
| 2023 | -149.54M | 27.69M | 212.57M |
VERV Cash Flow Statement (2019 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
Cash at beginning of period | 120.23M | 69.56M | 9.45M | 3.22M | 5.46M |
Operating activities | |||||
Net income | -200.06M | -157.38M | -120.31M | -45.70M | -19.29M |
| Adjustments to reconcile net income to cash generated by operating activities: | |||||
Depreciation and amortization | 5.45M | 2.80M | 1.53M | 1.32M | 106K |
Stock-based compensation expense | 35.11M | 22.47M | 7.07M | 850K | 446K |
| Deferred income tax benefit | 35.11M | 22.47M | 7.07M | 850K | 446K |
| Changes in operating assets and liabilities: | |||||
Accounts receivable, net | 0 | -1.01M | 0 | 0 | 0 |
Inventories | 0 | 1.01M | 0 | 0 | 0 |
Accounts payable | 3.91M | -5.21M | 6.82M | -1.89M | 1.73M |
Cash generated by operating activities | -149.54M | -122.33M | -77.88M | -35.26M | -7.44M |
Investing activities | |||||
Purchases Of Investments | -517.14M | -479.40M | -371.49M | -98.48M | -22.00M |
Investments In Property Plant And Equipment | -9.28M | -13.23M | -4.35M | -3.42M | -1.85M |
Acquisitions Net | 0 | 142.72M | 234.73M | 47.70M | 10.90M |
Cash generated by investing activities | 27.69M | -155.95M | -239.09M | -51.12M | -12.75M |
Financing activities | |||||
Common Stock Issued | 210.45M | 326.49M | 285.21M | 92.62M | 18.04M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | 0 | 0 | 0 |
Cash used in financing activities | 212.57M | 328.95M | 377.08M | 92.62M | 17.95M |
Net Change In Cash | 90.71M | 50.66M | 60.11M | 6.23M | -2.24M |
Cash at end of period | 210.95M | 120.23M | 69.56M | 9.45M | 3.22M |
| Data source | Data source | Data source |